ReviewRevista medica del Instituto Mexicano del Seguro Social2026
[Clinical spectrum, neuroimaging and therapeutic response to neurological syndromes associated with anti-GAD65].
Review in Revista medica del Instituto Mexicano del Seguro Social, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurological syndromes associated with anti-GAD65 antibodies include limbic encephalitis, cerebellar ataxia, drug-resistant epilepsy, stiff-person syndrome spectrum, and overlap syndromes. Their pathophysiology is linked to GABAergic dysfunction and neuronal hyperexcitability. In Latin America, evidence is limited; in a regional review, cases associated with anti-GAD antibodies represented 2.37% of antibody-confirmed autoimmune encephalitis, suggesting underreporting and incomplete clinical characterization. The objective of this study is to describe the clinical characteristics, neuroimaging findings, and therapeutic response in a series of anti-GAD65 cases, as well as to conduct a literature review. This is a retrospective series of four patients from the High Specialty Medical Unit No. 71, Torreón, Coahuila, Mexico. Clinical, imaging, and treatment variables were analyzed. Anti-GAD65 antibodies were determined in serum using ELISA. Diverse phenotypes were observed, with involvement of the hippocampus, cerebellum, and brainstem. Intravenous immunoglobulin, corticosteroids, and rituximab were used, with variable response. The heterogeneity of the anti-GAD65 spectrum hinders timely diagnosis and management, which is still not standardized. Larger regional studies are needed to improve characterization and optimize therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.